Cargando…

TREM2 expression in the brain and biological fluids in prion diseases

Triggering receptor expressed on myeloid cells 2 (TREM2) is an innate immune cell surface receptor that regulates microglial function and is involved in the pathophysiology of several neurodegenerative diseases. Its soluble form (sTREM2) results from shedding of the TREM2 ectodomain. The role of TRE...

Descripción completa

Detalles Bibliográficos
Autores principales: Diaz-Lucena, Daniela, Kruse, Niels, Thüne, Katrin, Schmitz, Matthias, Villar-Piqué, Anna, da Cunha, Jose Eriton Gomes, Hermann, Peter, López-Pérez, Óscar, Andrés-Benito, Pol, Ladogana, Anna, Calero, Miguel, Vidal, Enric, Riggert, Joachim, Pineau, Hailey, Sim, Valerie, Zetterberg, Henrik, Blennow, Kaj, del Río, Jose Antonio, Marín-Moreno, Alba, Espinosa, Juan Carlos, Torres, Juan María, Sánchez-Valle, Raquel, Mollenhauer, Brit, Ferrer, Isidre, Zerr, Inga, Llorens, Franc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113222/
https://www.ncbi.nlm.nih.gov/pubmed/33881612
http://dx.doi.org/10.1007/s00401-021-02296-1
_version_ 1783690813941743616
author Diaz-Lucena, Daniela
Kruse, Niels
Thüne, Katrin
Schmitz, Matthias
Villar-Piqué, Anna
da Cunha, Jose Eriton Gomes
Hermann, Peter
López-Pérez, Óscar
Andrés-Benito, Pol
Ladogana, Anna
Calero, Miguel
Vidal, Enric
Riggert, Joachim
Pineau, Hailey
Sim, Valerie
Zetterberg, Henrik
Blennow, Kaj
del Río, Jose Antonio
Marín-Moreno, Alba
Espinosa, Juan Carlos
Torres, Juan María
Sánchez-Valle, Raquel
Mollenhauer, Brit
Ferrer, Isidre
Zerr, Inga
Llorens, Franc
author_facet Diaz-Lucena, Daniela
Kruse, Niels
Thüne, Katrin
Schmitz, Matthias
Villar-Piqué, Anna
da Cunha, Jose Eriton Gomes
Hermann, Peter
López-Pérez, Óscar
Andrés-Benito, Pol
Ladogana, Anna
Calero, Miguel
Vidal, Enric
Riggert, Joachim
Pineau, Hailey
Sim, Valerie
Zetterberg, Henrik
Blennow, Kaj
del Río, Jose Antonio
Marín-Moreno, Alba
Espinosa, Juan Carlos
Torres, Juan María
Sánchez-Valle, Raquel
Mollenhauer, Brit
Ferrer, Isidre
Zerr, Inga
Llorens, Franc
author_sort Diaz-Lucena, Daniela
collection PubMed
description Triggering receptor expressed on myeloid cells 2 (TREM2) is an innate immune cell surface receptor that regulates microglial function and is involved in the pathophysiology of several neurodegenerative diseases. Its soluble form (sTREM2) results from shedding of the TREM2 ectodomain. The role of TREM2 in prion diseases, a group of rapidly progressive dementias remains to be elucidated. In the present study, we analysed the expression of TREM2 and its main sheddase ADAM10 in the brain of sporadic Creutzfeldt-Jakob disease (sCJD) patients and evaluated the role of CSF and plasma sTREM2 as a potential diagnostic marker of prion disease. Our data indicate that, compared to controls, TREM2 is increased in sCJD patient brains at the mRNA and protein levels in a regional and subtype dependent fashion, and expressed in a subpopulation of microglia. In contrast, ADAM10 is increased at the protein, but not the mRNA level, with a restricted neuronal expression. Elevated CSF sTREM2 is found in sCJD, genetic CJD with mutations E200K and V210I in the prion protein gene (PRNP), and iatrogenic CJD, as compared to healthy controls (HC) (AUC = 0.78–0.90) and neurological controls (AUC = 0.73–0.85), while CSF sTREM2 is unchanged in fatal familial insomnia. sTREM2 in the CSF of cases with Alzheimer’s disease, and multiple sclerosis was not significantly altered in our series. CSF sTREM2 concentrations in sCJD are PRNP codon 129 and subtype-related, correlate with CSF 14-3-3 positivity, total-tau and YKL-40, and increase with disease progression. In plasma, sTREM2 is increased in sCJD compared with HC (AUC = 0.80), displaying positive correlations with plasma total-tau, neurofilament light, and YKL-40. We conclude that comparative study of TREM2 in brain and biological fluids of prion diseases reveals TREM2 to be altered in human prion diseases with a potential value in target engagement, patient stratification, and disease monitoring. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00401-021-02296-1.
format Online
Article
Text
id pubmed-8113222
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-81132222021-05-13 TREM2 expression in the brain and biological fluids in prion diseases Diaz-Lucena, Daniela Kruse, Niels Thüne, Katrin Schmitz, Matthias Villar-Piqué, Anna da Cunha, Jose Eriton Gomes Hermann, Peter López-Pérez, Óscar Andrés-Benito, Pol Ladogana, Anna Calero, Miguel Vidal, Enric Riggert, Joachim Pineau, Hailey Sim, Valerie Zetterberg, Henrik Blennow, Kaj del Río, Jose Antonio Marín-Moreno, Alba Espinosa, Juan Carlos Torres, Juan María Sánchez-Valle, Raquel Mollenhauer, Brit Ferrer, Isidre Zerr, Inga Llorens, Franc Acta Neuropathol Original Paper Triggering receptor expressed on myeloid cells 2 (TREM2) is an innate immune cell surface receptor that regulates microglial function and is involved in the pathophysiology of several neurodegenerative diseases. Its soluble form (sTREM2) results from shedding of the TREM2 ectodomain. The role of TREM2 in prion diseases, a group of rapidly progressive dementias remains to be elucidated. In the present study, we analysed the expression of TREM2 and its main sheddase ADAM10 in the brain of sporadic Creutzfeldt-Jakob disease (sCJD) patients and evaluated the role of CSF and plasma sTREM2 as a potential diagnostic marker of prion disease. Our data indicate that, compared to controls, TREM2 is increased in sCJD patient brains at the mRNA and protein levels in a regional and subtype dependent fashion, and expressed in a subpopulation of microglia. In contrast, ADAM10 is increased at the protein, but not the mRNA level, with a restricted neuronal expression. Elevated CSF sTREM2 is found in sCJD, genetic CJD with mutations E200K and V210I in the prion protein gene (PRNP), and iatrogenic CJD, as compared to healthy controls (HC) (AUC = 0.78–0.90) and neurological controls (AUC = 0.73–0.85), while CSF sTREM2 is unchanged in fatal familial insomnia. sTREM2 in the CSF of cases with Alzheimer’s disease, and multiple sclerosis was not significantly altered in our series. CSF sTREM2 concentrations in sCJD are PRNP codon 129 and subtype-related, correlate with CSF 14-3-3 positivity, total-tau and YKL-40, and increase with disease progression. In plasma, sTREM2 is increased in sCJD compared with HC (AUC = 0.80), displaying positive correlations with plasma total-tau, neurofilament light, and YKL-40. We conclude that comparative study of TREM2 in brain and biological fluids of prion diseases reveals TREM2 to be altered in human prion diseases with a potential value in target engagement, patient stratification, and disease monitoring. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00401-021-02296-1. Springer Berlin Heidelberg 2021-04-21 2021 /pmc/articles/PMC8113222/ /pubmed/33881612 http://dx.doi.org/10.1007/s00401-021-02296-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Diaz-Lucena, Daniela
Kruse, Niels
Thüne, Katrin
Schmitz, Matthias
Villar-Piqué, Anna
da Cunha, Jose Eriton Gomes
Hermann, Peter
López-Pérez, Óscar
Andrés-Benito, Pol
Ladogana, Anna
Calero, Miguel
Vidal, Enric
Riggert, Joachim
Pineau, Hailey
Sim, Valerie
Zetterberg, Henrik
Blennow, Kaj
del Río, Jose Antonio
Marín-Moreno, Alba
Espinosa, Juan Carlos
Torres, Juan María
Sánchez-Valle, Raquel
Mollenhauer, Brit
Ferrer, Isidre
Zerr, Inga
Llorens, Franc
TREM2 expression in the brain and biological fluids in prion diseases
title TREM2 expression in the brain and biological fluids in prion diseases
title_full TREM2 expression in the brain and biological fluids in prion diseases
title_fullStr TREM2 expression in the brain and biological fluids in prion diseases
title_full_unstemmed TREM2 expression in the brain and biological fluids in prion diseases
title_short TREM2 expression in the brain and biological fluids in prion diseases
title_sort trem2 expression in the brain and biological fluids in prion diseases
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113222/
https://www.ncbi.nlm.nih.gov/pubmed/33881612
http://dx.doi.org/10.1007/s00401-021-02296-1
work_keys_str_mv AT diazlucenadaniela trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT kruseniels trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT thunekatrin trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT schmitzmatthias trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT villarpiqueanna trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT dacunhajoseeritongomes trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT hermannpeter trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT lopezperezoscar trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT andresbenitopol trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT ladoganaanna trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT caleromiguel trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT vidalenric trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT riggertjoachim trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT pineauhailey trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT simvalerie trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT zetterberghenrik trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT blennowkaj trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT delriojoseantonio trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT marinmorenoalba trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT espinosajuancarlos trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT torresjuanmaria trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT sanchezvalleraquel trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT mollenhauerbrit trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT ferrerisidre trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT zerringa trem2expressioninthebrainandbiologicalfluidsinpriondiseases
AT llorensfranc trem2expressioninthebrainandbiologicalfluidsinpriondiseases